Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study.

Détails

Ressource 1Télécharger: BIB_72BB76FC0007.P001.pdf (379.35 [Ko])
Etat: Serval
Version: de l'auteur
ID Serval
serval:BIB_72BB76FC0007
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study.
Périodique
Plos Medicine
Auteur(s)
Rosanas-Urgell A., Lin E., Manning L., Rarau P., Laman M., Senn N., Grimberg B.T., Tavul L., Stanisic D.I., Robinson L.J., Aponte J.J., Dabod E., Reeder J.C., Siba P., Zimmerman P.A., Davis T.M., King C.L., Michon P., Mueller I.
ISSN
1549-1676 (Electronic)
ISSN-L
1549-1277
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
9
Numéro
e1001305
Pages
1-11
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.Publication Status: ppublish
Résumé
BACKGROUND: The erythrocyte polymorphism, Southeast Asian ovalocytosis (SAO) (which results from a 27-base pair deletion in the erythrocyte band 3 gene, SLC4A1Δ27) protects against cerebral malaria caused by Plasmodium falciparum; however, it is unknown whether this polymorphism also protects against P. vivax infection and disease.
METHODS AND FINDINGS: The association between SAO and P. vivax infection was examined through genotyping of 1,975 children enrolled in three independent epidemiological studies conducted in the Madang area of Papua New Guinea. SAO was associated with a statistically significant 46% reduction in the incidence of clinical P. vivax episodes (adjusted incidence rate ratio [IRR] = 0.54, 95% CI 0.40-0.72, p<0.0001) in a cohort of infants aged 3-21 months and a significant 52% reduction in P. vivax (blood-stage) reinfection diagnosed by PCR (95% CI 22-71, p = 0.003) and 55% by light microscopy (95% CI 13-77, p = 0.014), respectively, in a cohort of children aged 5-14 years. SAO was also associated with a reduction in risk of P. vivax parasitaemia in children 3-21 months (1,111/µl versus 636/µl, p = 0.011) and prevalence of P. vivax infections in children 15-21 months (odds ratio [OR] = 0.39, 95% CI 0.23-0.67, p = 0.001). In a case-control study of children aged 0.5-10 years, no child with SAO was found among 27 cases with severe P. vivax or mixed P. falciparum/P. vivax malaria (OR = 0, 95% CI 0-1.56, p = 0.11). SAO was associated with protection against severe P. falciparum malaria (OR = 0.38, 95% CI 0.15-0.87, p = 0.014) but no effect was seen on either the risk of acquiring blood-stage infections or uncomplicated episodes with P. falciparum. Although Duffy antigen receptor expression and function were not affected on SAO erythrocytes compared to non-SAO children, high level (>90% binding inhibition) P. vivax Duffy binding protein-specific binding inhibitory antibodies were observed significantly more often in sera from SAO than non-SAO children (SAO, 22.2%; non-SAO, 6.7%; p = 0.008).
CONCLUSIONS: In three independent studies, we observed strong associations between SAO and protection against P. vivax malaria by a mechanism that is independent of the Duffy antigen. P. vivax malaria may have contributed to shaping the unique host genetic adaptations to malaria in Asian and Oceanic populations. Please see later in the article for the Editors' Summary.
Mots-clé
Case-Control Studies, Cohort Studies, Elliptocytosis, Hereditary/epidemiology, Malaria, Vivax/epidemiology, Microscopy, Papua New Guinea/epidemiology, Polymerase Chain Reaction
Pubmed
Web of science
Open Access
Oui
Création de la notice
11/02/2013 17:41
Dernière modification de la notice
08/05/2019 20:22
Données d'usage